Gliclazide is the second generation of oral sulfonylurea hypoglycemic drugs, which can not only treat diabetic metabolic disorders, but also prevent vascular diseases, improve retinopathy and renal function. It is suitable for non-insulin-dependent diabetes, obesity type diabetes, senile diabetes and diabetes with cardiovascular complications. It has gradually become a first-line drug. However, because gliclazide is short in water solubility, slow in dissolution rate and individual difference in bioavailability, it affects the clinical application of gliclazide.
Hydroxypropyl beta cyclodextrin is a good pharmaceutical excipient with broad prospects for development. It has high water solubility and no toxic to the kidney. It has almost no stimulation to the muscles and mucous membrane. After the inclusion of HPBCD, the solubility and dissolution rate of the drug can be increased, and the bioavailability and stability of the drug can be increased.